DICE Therapeutics’ $204 Million Initial Public Offering

Fenwick & West advised DICE Therapeutics on the deal.

DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17 per share. The gross proceeds from the offering were $204 million.

The shares began trading on the Nasdaq Global Market on September 15, 2021. BofA Securities, SVB Leerink and Evercore ISI acted as joint bookrunning managers for the offering.

The Fenwick transaction team includes corporate partners Matthew Rossiter (Picture), Robert Freedman and Amanda Rose and associates Michael Shaw, Myles Gutenkunst, David Kryzanovsky, Frances Fuqua and Riddhi Adhikari; executive compensation and employee benefits partner Marshall Mort and associates Christophe Delrieu and Jonathan Stephenson; and tax partner Will Skinner.

Involved fees earner: Riddhi Adhikari – Fenwick & West LLP; Christophe Delrieu – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Frances Fuqua – Fenwick & West LLP; Myles Gutenkunst – Fenwick & West LLP; David Kryzanovsky – Fenwick & West LLP; Marshall Mort – Fenwick & West LLP; Amanda Rose – Fenwick & West LLP; Matthew Rossiter – Fenwick & West LLP; Michael Shaw – Fenwick & West LLP; William Skinner – Fenwick & West LLP; Jonathan Stephenson – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: DICE Therapeutics;

Author: Martina Bellini